â– LECTURE OVERVIEW: Benign Prostatic Hyperplasia (BPH) is an age-related, non-malignant proliferation of the prostatic stromal and epithelial cells.
â– PATHWAY ANALYSIS:
1. Transition Zone: Hyperplasia occurs selectively in the central periurethral Transition Zone, compressing the prostatic urethra and obstructing urine outflow.
2. Dihydrotestosterone (DHT) Influence: Driven by DHT, synthesized from testosterone by 5-alpha-reductase in prostatic stromal cells.
3. Lower Urinary Tract Symptoms (LUTS): Presents with urinary frequency, urgency, nocturia, a weak urinary stream, hesitancy, and incomplete emptying.
4. Pharmacotherapy Approaches:
- Alpha-1 Adrenergic Blockers: Selectively block alpha-1A receptors on the prostatic urethra and bladder neck, relaxing smooth muscle to rapidly improve urine flow.
- 5-Alpha-Reductase Inhibitors: Block 5-alpha-reductase, preventing testosterone's conversion to DHT to shrink the prostate over 6-12 months.
â– RADIOGRAPHIC DIAGNOSTIC CRITERIA:
Imaging modalities (such as high-resolution CT, contrast-enhanced MRI, and point-of-care ultrasound) show characteristic density shifts, enhancement patterns, or structural deviations.
â– EMERGENCY DECREES & FAST-TRACK RESPONSES:
Upon presentation with extreme physiological disruption, initiate immediate volume restoration and broad-spectrum metabolic stabilization.
[HY-BOARD-1257]
🌟 Dynamic Clinical Key:
Alpha-1 blockers (e.g., Tamsulosin, Silodosin) provide rapid symptom relief but do not shrink the prostate. 5-alpha-reductase inhibitors (e.g., Finasteride, Dutasteride) are used for long-term reduction of prostate size, helping to prevent acute urinary retention. Always correlate imaging signs with clinical presentation to avoid unnecessary surgical explorations of benign incidentalomas. Confirm central vital markers continually rather than relying solely on peripheral readings.